Advertisement
Novo Nordisk A/S

Novo Nordisk A/S (NVO) Stock Overview

Explore Novo Nordisk A/S’s financial performance, market position, analyst ratings, and future outlook.

NVOā—NYSE
HealthcareBiotechnology
$41.02
$1.93(4.50%)
U.S. Market opens in NaNh NaNm
Advertisement

Novo Nordisk A/S (NVO)

Meyka AI Score

Z

Key Financials

Market Cap182.2B
P/E Ratio9.73
EPS (TTM)$4.26
ROE0.66%
Fundamental Analysis

AI Price Forecasts

1 Month$33.15
3 Months$56.35
1 Year Target$0.00

NVO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Novo Nordisk A/S (NVO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 39.24, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 9.73 and a market capitalization of 182.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-4.54%
5-Day Change
-4.01%
1-Month Change
-10.99%
3-Month Change
6.29%
6-Month Change
-12.33%
Year-to-Date (YTD) Change
-19.41%
1-Year Change
-45.66%
3-Year Change
-48.56%
5-Year Change
-0.33%
All-Time (Max) Change
25528.13%

Contact Information

45 44 44 88 88
Novo Alle 1, Bagsvaerd, NaN, 2880

Company Facts

77,406 Employees
IPO DateApr 30, 1981
CountryDK
Actively Trading

Frequently Asked Questions